OT
Odyssey Therapeutics, Inc.
SEC filingBiotechnology · Boston, MA
Amount raised$214Msold at filing
Total offering$214M
Investors in the raise55count reported to the SEC
FiledDec 4, 2025first sale Jun 16, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Valerie D. OdegardDirector
Carl D. GordonDirector
Carolyn F. NgDirector
Gary D. GlickExecutive Officer, Director
Timothy D. WalbertDirector
Paulina D. HillDirector
Nan D. LiDirector
Jeffrey D. LeidenDirector
Jason F. HaasExecutive Officer
Nia F. TatsisDirector
Ksenija F. PavleticDirector
Shelley F. ChuDirector
Executive officers, directors and promoters as listed on the Form D.